JPMorgan, Eli Lilly and Thor - the latest insider picks

08.11.2019 / 04:30

Rating:

Insider insider buying can be a pretty encouraging sign for any potential investor. However, this reporting season has shortened the buying time for many investors, and some insiders have bought shares since the reports have already been published.

According to the general opinion, insiders only buy shares of one company for one reason - they believe that the share price will go up, and they want to profit from it. So these types of actions can inspire many investors to follow them, especially in times of uncertainty.

Here are the insider actions of the past week.

A director at JPMorgan purchased 16,000 shares at a price of $ 124.64 through a trust fund. The transaction totaled more than $ 1.99 million. Keep in mind that earlier this month some of the directors sold their shares.

JPMorgan was one of the first banks in the order of the season to report on the strong start of the season. The last close was at $ 126.03.

CEO David Ricks of Eli Lilly and one of the directors have bought more than 6,400 shares together in the last week. The shares were bought in a range between $ 107.45 and $ 108.38 per share, with the whole transaction being $ 700,000.

Eli Lilly published better-than-expected reports and raised its growth prospects. The company closed at $ 110.20.

Thor Industries CEO Robert Martin bought 10,000 shares in a range of $ 58.67 and $ 58.86, which cost him more than $ 588,000. So he increased his total holdings to 222,000.

Thor released better reports late last month and soon increased their dividend. Their last shares were trading at $ 67.10.

Internal purchases continue with Assured Guaranty, with some activity on Opko Health and WesBanco being detected.

Trader Martin Nikolov

Read more:

RECCOMEND WAS THIS POST USEFUL FOR YOU?
If you think, we can improve that section,
please comment. Your oppinion is imortant for us.

WARNING: Any news, opinions, research, data or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. Varchev Finance Ltd. expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information. Varchev Finance Ltd. may provide information, quotes, references and links to or from other sites and blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the sites, blogs or other sources of information.

Varchev Finance

Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.

Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006

The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

Disclaimer:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

JPMorgan, Eli Lilly and Thor - the latest insider picks

London

Universal numbers